CareDx, Inc (NASDAQ:CDNA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of CareDx, Inc (NASDAQ:CDNA) have been assigned an average rating of “Moderate Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $28.33.

Several equities analysts have weighed in on the stock. BTIG Research dropped their target price on shares of CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, November 5th. StockNews.com cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and reduced their target price for the company from $28.00 to $24.00 in a research note on Wednesday, January 15th. Finally, HC Wainwright reissued a “neutral” rating and set a $26.00 price target on shares of CareDx in a research report on Tuesday, January 14th.

Institutional Trading of CareDx

Several hedge funds and other institutional investors have recently bought and sold shares of CDNA. Quarry LP acquired a new stake in shares of CareDx during the third quarter worth $27,000. Thompson Davis & CO. Inc. boosted its holdings in shares of CareDx by 6.3% in the 4th quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company’s stock valued at $344,000 after purchasing an additional 950 shares during the last quarter. Royce & Associates LP grew its stake in shares of CareDx by 0.3% during the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock valued at $12,280,000 after buying an additional 1,000 shares during the period. Hsbc Holdings PLC increased its holdings in shares of CareDx by 6.9% during the 4th quarter. Hsbc Holdings PLC now owns 17,131 shares of the company’s stock worth $365,000 after buying an additional 1,109 shares during the last quarter. Finally, Legal & General Group Plc raised its position in shares of CareDx by 1.3% in the 4th quarter. Legal & General Group Plc now owns 89,751 shares of the company’s stock worth $1,922,000 after buying an additional 1,118 shares during the period.

CareDx Stock Performance

Shares of CDNA stock opened at $21.37 on Tuesday. The stock has a fifty day moving average price of $22.66 and a 200 day moving average price of $25.36. The stock has a market cap of $1.15 billion, a PE ratio of -7.91 and a beta of 1.87. CareDx has a 1 year low of $7.42 and a 1 year high of $34.84.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.